![](/images/graphics-bg.png)
A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation
Joint Authors
Campistol, Josep
Del Carmen Rial, Maria
Russ, Graeme
Raffaele, Pablo
Nashan, Bjorn
Keown, Paul A.
Kasiske, Bertram L.
Pescovitz, Mark D.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-16, 16 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-08-09
Country of Publication
Egypt
No. of Pages
16
Main Subjects
Abstract EN
This prospective pharmacoepidemiological study examined treatment and outcomes in patients converted to sirolimus (SRL) after renal transplantation.
484 subjects in 36 centres in 7 countries were followed for up to 5 years.
Principal reasons for conversion were declining graft function (146/484, 30%) and side effects of prior therapy (144/484, 30%) and the major treatment combinations after conversion were SRL ± MMF (62%), SRL + TAC (21.5%), SRL + CSA (16.5%).
The cumulative probability of biopsy-confirmed acute rejection (BCAR) was 5% (n=22), death-censored graft loss 12% (n=56) and death 6% (n=22), and there was no significant relationship to the treatment combination employed.
Median calculated creatinine clearance was 48.4 (29.3, 64.5) mL/min at conversion, rising to 54.1 (41.2, 69.0) mL/min at month 1, 55.7 (39.0, 73.0) mL/min at month 12, 58.6 (39.7, 75.2) mL/min at two years and 60.9 (36.0, 77.0) mL/min at three years post-conversion.
The most common adverse events were hypertension (47%), hyperlipidemia (26%), urinary tract infections (25%), anaemia (24%) and diarrhea (14%), and cardiac events, hyperlipemia and CMV infection were more common in patients converted during the first year.
SRL was most frequently combined with MMF after conversion, but principal clinical outcomes were not significantly influenced by the treatment combination employed in normal practice.
American Psychological Association (APA)
Kasiske, Bertram L.& Nashan, Bjorn& Del Carmen Rial, Maria& Raffaele, Pablo& Russ, Graeme& Campistol, Josep…[et al.]. 2012. A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation. Journal of Transplantation،Vol. 2012, no. 2012, pp.1-16.
https://search.emarefa.net/detail/BIM-446942
Modern Language Association (MLA)
Kasiske, Bertram L.…[et al.]. A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation. Journal of Transplantation No. 2012 (2012), pp.1-16.
https://search.emarefa.net/detail/BIM-446942
American Medical Association (AMA)
Kasiske, Bertram L.& Nashan, Bjorn& Del Carmen Rial, Maria& Raffaele, Pablo& Russ, Graeme& Campistol, Josep…[et al.]. A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation. Journal of Transplantation. 2012. Vol. 2012, no. 2012, pp.1-16.
https://search.emarefa.net/detail/BIM-446942
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-446942